Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
cyproterone acetate + ethinylestradiol
- Development stage
- Unknown
- Lead developer
- Swiss Pharma
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Cyestra is a combination pharmaceutical product containing cyproterone acetate and ethinylestradiol, developed and manufactured by Swiss Pharmaceuticals (Pvt) Ltd. Cyproterone acetate is a synthetic progestogen with potent anti-androgenic properties, while ethinylestradiol is a synthetic estrogen. This combination is primarily indicated for the treatment of moderate to severe androgen-dependent diseases in women, including acne (with or without seborrhea), hirsutism, and androgenetic alopecia. Additionally, it serves as an effective oral contraceptive by inhibiting ovulation and altering cervical mucus. The anti-androgenic component works by competitively inhibiting the binding of dihydrotestosterone to its receptors and reducing the concentration of circulating androgens through the suppression of luteinizing hormone.
- Brand names
- Cyestra
- Other names
- cyproterone acetate and ethinylestradiolCPA/EE
02
Targets
ESR2 (ERβ)PR (Progesterone receptor)AR (Adrenergic receptors)ESR1 (ERα)
Beyond the preview
Go deeper on cyproterone acetate + ethinylestradiol.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on cyproterone acetate + ethinylestradiol.